- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
University of Colorado Denver - Articles and news items
Corticosteroids and mass spectrometry; latest applications using LC/MS3.
Multi-analyte LC-MS/MS assays for the quantification of endogenous compounds during the development of drugs and companion diagnostics…
Issue 5 2012, Polymers / 22 October 2012 / Vinod B. Damodaran and Jessica M. Joslin, Department of Chemistry, Colorado State University and Melissa M. Reynolds, Department of Chemistry and School of Biomedical Engineering, Colorado State University
Biodegradable polymers comprise an important class of biomaterials due to their ability to satisfy short-term requirements for medical applications where a permanent implant is not required. However, current biodegradable polymers suffer from undesirable chemical properties that lead to improper elimination from the body and potentially toxic by-products. Additionally, medical polymers cause adverse biological responses at the material-body interface and therefore require some functionality to regulate such processes. To overcome problems such as processability and solubility issues, we describe our approach to synthesising new classes of biodegradable polymers with desirable structural features that exhibit good solubility, tunable degradation and non-toxic by-products. Additionally, these polymers are functionalised for release of the therapeutic agent, nitric oxide (NO), which serves to regulate initial and long-term biological responses.
Two different classes of modified polymer are presented; the first is based on poly(lactic-coglycolic acid) (PLGH) and the second on dextran. We present the NO release profiles associated with several polymer derivatives of both classes along with their degradation timelines. Overall, the PLGH derivatives are processable as films or fibres and show promise in wound healing and tissue engineering applications while the dextran materials are feasible as prodrugs in the cardiovascular system.
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Butterworth Laboratories Ltd CAPSUGEL NV Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) Eurofins BioPharma Product Testing EUROGENTEC F.P.S. Food and Pharma Systems Srl GE Analytical Instruments IDBS JEOL Europe Kaiser Optical Systems Inc. L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Lonza MA Business Metrohm Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Ocean Optics Panasonic Biomedical Sales Europe B.V. Peak Scientific ReAgent Russell Finex Limited Sentronic GmbH Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Viavi Solutions, Inc Watson-Marlow Fluid Technology Group Wickham Laboratories Limited WITec GmbH Xylem Analytics YMC Europe GmbH Yusen Logistics